Linked Data API

Show Search Form

Search Results

436266
registered interest false more like this
date less than 2015-12-08more like thismore than 2015-12-08
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health remove filter
answering dept sort name Health more like this
hansard heading Lumacaftor/ivacaftor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, when he expects Orkambi to be appraised by NICE. more like this
tabling member constituency York Outer remove filter
tabling member printed
Julian Sturdy more like this
uin 19234 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-12-15more like thismore than 2015-12-15
answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. NICE’s anticipated publication date for this guidance is July 2016. Further information is available at:</p><br /><p>www.nice.org.uk/guidance/indevelopment/gid-tag530</p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-12-15T16:20:22.32Zmore like thismore than 2015-12-15T16:20:22.32Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4079
label Biography information for Julian Sturdy more like this